These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 28620691)

  • 1. Biomarkers for the Management of Castration-Resistant Prostate Cancer: We Are Not There Yet.
    Petrylak DP; Crawford ED
    Target Oncol; 2017 Aug; 12(4):401-412. PubMed ID: 28620691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 3. The Evolving Biology of Castration-Resistant Prostate Cancer: Review of Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
    Geethakumari PR; Cookson MS; Kelly WK;
    Oncology (Williston Park); 2016 Feb; 30(2):187-95, 199. PubMed ID: 26888794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancer.
    Seisen T; Rouprêt M; Gomez F; Malouf GG; Shariat SF; Peyronnet B; Spano JP; Cancel-Tassin G; Cussenot O
    Cancer Treat Rev; 2016 Jul; 48():25-33. PubMed ID: 27327958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in systemic therapies for metastatic castration-resistant prostate cancer.
    Pant MK; Abughaban A; Aragon-Ching JB
    Future Oncol; 2014 Nov; 10(14):2213-26. PubMed ID: 25471035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCTP Has a Crucial Role in the Different Stages of Prostate Cancer Malignant Progression.
    Baylot V; Karaki S; Rocchi P
    Results Probl Cell Differ; 2017; 64():255-261. PubMed ID: 29149413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer.
    Conteduca V; Mosca A; Brighi N; de Giorgi U; Rescigno P
    Cells; 2021 Jan; 10(1):. PubMed ID: 33478015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer.
    Aziz A; Kempkensteffen C; May M; Lebentrau S; Burger M; Chun FK; Brookman-May S
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):649-66. PubMed ID: 25905802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequencing Treatment for Castration-Resistant Prostate Cancer.
    Handy CE; Antonarakis ES
    Curr Treat Options Oncol; 2016 Dec; 17(12):64. PubMed ID: 27822685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical phenotypes of castration-resistant prostate cancer.
    Zhang T; Armstrong AJ
    Clin Adv Hematol Oncol; 2013 Nov; 11(11):707-18. PubMed ID: 24896544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular landscape of prostate cancer: implications for current clinical trials.
    Khemlina G; Ikeda S; Kurzrock R
    Cancer Treat Rev; 2015 Nov; 41(9):761-6. PubMed ID: 26210103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PBX3 is a putative biomarker of aggressive prostate cancer.
    Ramberg H; Grytli HH; Nygård S; Wang W; Ögren O; Zhao S; Løvf M; Katz B; Skotheim RI; Bjartell A; Eri LM; Berge V; Svindland A; Taskén KA
    Int J Cancer; 2016 Oct; 139(8):1810-20. PubMed ID: 27273830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal factors involved in human prostate cancer development, progression and castration resistance.
    Eiro N; Fernandez-Gomez J; Sacristán R; Fernandez-Garcia B; Lobo B; Gonzalez-Suarez J; Quintas A; Escaf S; Vizoso FJ
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):351-359. PubMed ID: 27787597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing systemic therapies in metastatic castration-resistant prostate cancer.
    Liu JJ; Zhang J
    Cancer Control; 2013 Jul; 20(3):181-7. PubMed ID: 23811702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers in castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):115-8. PubMed ID: 24892256
    [No Abstract]   [Full Text] [Related]  

  • 20. YB-1: The key to personalised prostate cancer management?
    Bates M; Boland A; McDermott N; Marignol L
    Cancer Lett; 2020 Oct; 490():66-75. PubMed ID: 32681926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.